Venetoclax + Dexamethasone + Inotuzumab Ozogamicin
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
Trial Timeline
Sep 24, 2021 → Dec 23, 2026
NCT ID
NCT05016947About Venetoclax + Dexamethasone + Inotuzumab Ozogamicin
Venetoclax + Dexamethasone + Inotuzumab Ozogamicin is a phase 1 stage product being developed by AbbVie for B-cell Acute Lymphoblastic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT05016947. Target conditions include B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05016947 | Phase 1 | Active |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia